RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.June 16, 2023 - Merck closed its $10.8 billion acquisition of Prometheus Biosciences, as a bolt-on acquisition, setting the stage for the drugmaker’s pursuit of an immunology blockbuster.
https://endpts.com/merck-close-10-8b-deal-with-prometheus/ But buying out the San Diego immunology specialist has not satisfied Merck’s appetite for M&A, executives said during the company's second-quarter 2023 earnings call. February 01 2024 - Merck's (MSD) CEO Robert Davis went on record by saying that Merck's acquisition "sweet spot " is US$ 10+ Billion, as had been suggested as Big Pharma's sweet spot around 12 month ago.
During JPM 2024 CEO Robert Davis and research chief Dean Li, M.D., Ph.D., remained consistent with previous comments that dealmaking decisions are led by the best science, not the best financial opportunity. Davis says is it just so happens that Merck's "sweet spot" have been deals in the $0-15 billion range. The New Jersey pharma acquired immunology biotech Prometheus for $10.8 billion and is paying Daichii Sankyo at least $5.5 billion over two years for a batch of antibody-drug conjugates.
Now think of the future, and precision medicine and the development of an I/O combination therapy, involving a bi or trispecific or ADC, in combination with pembrolizumab and ONCY's pelareorep, for the treatment of multiple cancers. This future is fast approaching.
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=35863370